BGN and urinary bladder cancer: In the present study it is concluded that biglycan is also an inhibitor of bladder cancer progression as suggested from increased tumor progression of mice receiving xenografts after knock-down of BGN and the clinical follow up showing that patients with low BGN mRNA expression have a worse prognosis compared to patients with high BGN mRNA expression in tumor biopsies.